- Home
- / Rubius Therapeutics
Rubius Therapeutics
Market Capitalization
$20 M
2022-11-21
Rubius Therapeutics Summary
Company summary
- Overview
- Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://www.rubiustx.com/
- Cybersecurity rating
- ESG rating
Key people
Dannielle Appelhans, Chief Operating Officer
Spencer Fisk, Chief Technical Operations Officer
Maiken Keson-Brookes, Chief Legal Officer and Corporate Secretary
LocationsView all
2 locations detected
Cambridge, MA HQ
United States
399 Binney St #300
Smithfield, RI
United States
100 Technology Way
Rubius Therapeutics Financials
Summary financials
- Net income (Q3, 2022)
- ($62.9M)
- Cash (Q3, 2022)
- $103.9M
- EBIT (Q3, 2022)
- ($61.6M)
- Enterprise value
- $26.8M
